New Study Suggests Lung Transplants Could Benefit Terminal Cancer Patients

Islamabad, Pakistan Jul 12, 2026 ALN: New Insights on Lung Transplants for Cancer Patients

The long-held guidance that patients with stage IV lung cancer should not be eligible for lung transplants is being challenged by findings from a new study, at least for a subset of patients. This shift in perspective is particularly significant given the high mortality rates associated with advanced lung cancer, which has traditionally been viewed as a terminal illness with limited treatment options. The implications of this study could reshape the approach to treatment for terminal cancer patients, potentially expanding the criteria for lung transplantation.

Tracking adults with terminal lung cancer confined to the lungs who were out of treatment options, doctors found lung transplantation was associated with substantially better early survival than medical management alone. This finding is particularly noteworthy as it suggests that, under certain circumstances, lung transplants may provide a viable option for patients who have exhausted other therapeutic avenues.

In the study, seventeen such patients underwent lung transplants while 81 received medical management alone. The results were striking; reported in JAMA, the study indicated that a year later, every transplanted patient was still alive, compared with fewer than half of the similar cancer patients treated with medical therapies. This stark contrast in survival rates raises important questions about the criteria used to determine eligibility for lung transplants in cancer patients.

While stage IV lung cancer has usually spread beyond the lungs, patients in this study belonged to a subset whose cancer remains confined to both lungs even as it progresses to respiratory failure. This distinction is crucial, as it highlights that their immediate cause of death is often not widespread systemic cancer, but rather progressive failure of cancer-filled lungs. Understanding this nuance could lead to more targeted approaches in managing advanced lung cancer and potentially improve patient outcomes.

“This work changes what we can imagine for a highly selected group of patients who were previously considered beyond the reach of curative-intent intervention,” study leader Dr. Ankit Bharat of Northwestern Medicine in Chicago said in a statement. This statement underscores the potential for reevaluating treatment protocols for terminal cancer patients, particularly those with localized disease that has not metastasized to other organs.

The 100% one-year survival rate among the cancer patients who underwent lung transplants was also higher than the 88% rate among patients who received lung transplants for traditional reasons. This finding suggests that giving lungs to certain advanced cancer patients is not a waste of donated organs that are in short supply. In a time when organ donation shortages are a pressing concern, this study could lead to a reevaluation of how organs are allocated, particularly for patients with terminal illnesses.

“When the cancer is rigorously proven to be confined to the lungs, when standard therapies have been exhausted, and when the lungs themselves have become the life-limiting organ, transplantation may offer a new path forward,” Bharat said. This statement reflects a growing recognition of the need for innovative approaches in treating advanced cancer and highlights the importance of ongoing research in this area.

Men More Likely to Be Diagnosed with Late-Stage Cancer

Cancer is found at late stages more often in men than in women, according to a U.S. study that may provide insight into gender discrepancies in cancer outcomes. The more advanced the disease at diagnosis, the worse the prognosis tends to be, making this finding particularly relevant for public health strategies aimed at improving early detection and treatment of cancer.

Reviewing more than 2.4 million cases diagnosed from 2015 to 2022, researchers identified 16 cancers in which men were significantly more likely than women to be diagnosed after the disease had spread to local lymph nodes. Such regional-stage diagnoses were 151% more likely in men than in women with tongue cancer, 93% more likely with salivary gland cancer, 80% more likely with oropharyngeal cancer, 74% more likely with thyroid cancer, and 67% more likely with stomach cancer, researchers noted in a report in Cancer Epidemiology, Biomarkers & Prevention.

Late-stage cancers that have spread to other organs were also more common than localized tumors in men versus women for 17 cancer sites, with the largest differences seen in melanoma and cancers of the tongue, thyroid, salivary gland, and stomach. These findings suggest a need for targeted interventions aimed at improving awareness and screening practices among men to help reduce the incidence of late-stage diagnoses.

For a small number of cancer sites – including the larynx and the bladder – men were less likely than women to be diagnosed at later stages. This variation emphasizes the complexity of cancer diagnoses and the need for further research to understand the underlying factors contributing to these discrepancies.

These patterns persisted across different races, ethnicities, and neighborhood income levels, indicating that the issue is not confined to specific demographic groups. One explanation could be differences in cancer screening rates, study leader Beth Maclin of the U.S. National Cancer Institute said in a statement. This suggests that public health initiatives aimed at increasing screening and awareness could be beneficial in reducing late-stage cancer diagnoses.

Moreover, women tend to see doctors more often than men, which could mean more opportunities for clinicians to catch cancer symptoms earlier. Clinicians may also perceive cancer symptoms differently in males and females, leading to different types of diagnostic tests. This gender-based difference in healthcare access and perceptions could play a significant role in the observed disparities in cancer outcomes.

New Discoveries in Blood Cell Production

In a related area of research, scientists have discovered that the manufacturing of red blood cells by the human body works differently than previously thought. This groundbreaking finding overturns decades of assumptions based largely on animal research, indicating that our understanding of human biology is still evolving.

The findings, led by Dr. Peng Ji of the Feinberg School of Medicine of Northwestern University in Chicago, show that the structures known as erythroblastic islands, which have long been understood to act as “nurseries” for red blood cell maturation, function differently in humans compared to mice. Ji’s team used advanced microscopic techniques to directly observe these structures, challenging long-standing beliefs based on previous studies.

“For decades, our understanding of these structures has come almost entirely from mouse studies,” Ji said in a statement. “Most experiments relied on isolating cells and studying them in flat, two-dimensional systems, which disrupt their native organization.” This statement highlights the limitations of animal models in biomedical research and underscores the need for more human-specific studies to improve our understanding of human biology.

In humans, researchers found no organizing center for these erythroid cells. “In humans, the erythroid cells cluster on their own without needing a central macrophage,” Ji said. “That overturns a long-standing assumption that human blood formation mirrors what we see in mice.” This discovery represents a fundamental shift in understanding how the body produces its most abundant cell type, with potential implications for how we understand and treat blood disorders.

“This is essentially a paradigm shift,” Ji said. “Much of biomedical research depends on mouse models. If the underlying biology is different, that affects how we interpret disease mechanisms and develop therapies.” This statement underscores the importance of translating findings from animal models to human applications and emphasizes the need for ongoing research in this area.

The findings also raise new questions about how the human body compensates for the absence of a central macrophage. In mice, macrophages play a critical role in clearing the nuclei expelled during red blood cell maturation. Understanding how humans achieve this function could lead to new insights into blood production and related disorders.

Future research will focus on that and other questions, Ji said, indicating a commitment to advancing our understanding of blood cell production and its implications for human health. As researchers continue to explore these new frontiers, the potential for developing novel therapies and improving patient outcomes remains an exciting prospect.